Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.
ColoPrint provides a definitive relapse risk assessment for 100 percent of all stage II patients and eliminates the gray area of indeterminate results found in 70 percent of patients using clinical and pathologic factors such as T4-stage and Microsatellite Instability (MSI) status. In combination with clinical factors, ColoPrint further individualizes the relapse risk assessment for colon cancer patients. This definitive risk stratification tool improves the identification of patients most likely to benefit from adjuvant therapy.
"ColoPrint's definitive results (either high or low risk with no in between) will enable doctors to choose treatment plans for colon cancer patients that are customized for each patient's individual needs," said David Macdonald, Agendia CEO. "We expect ColoPrint to be well received amongst physicians and patients for a more personalized management of this disease."
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths